Biomedical engineering & implants

01Overview and value chain

Markers: [EC: EU MDR 2017/745 / China VBP (Volume-Based Procurement) | OECD: Biotech & health — medical devices & implants | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Biomedical engineering & implants is the design and manufacture of devices that interact structurally or electrically with the human body — titanium joint prostheses, cardiovascular stents and valves, cardiac pacemakers and defibrillators, neurointerfaces and tissue-engineered biomaterials. It is the highest-value segment of medical technology: Stryker alone reported $11.2 billion in orthopedic sales for 2025, up 4.7% year on year, and Siemens Healthineers reached €23.4 billion in FY25 revenue with €12.1 billion from imaging. The field is bifurcating along two axes — precision and cost. On the precision axis, robotic-assisted arthroplasty and 3D-printed personalized implants command a large innovation premium (a Mako robotic system is a roughly $1 million capital purchase and over a million Stryker robotic procedures have been performed). On the cost axis, China’s Volume-Based Procurement (VBP) tenders collapsed the price of a coronary stent from about 13,000 yuan to roughly 700 yuan, shifting volume to domestic manufacturers. Underneath both axes, every implant is gated by a device regulator — FDA 510(k)/PMA in the US, the EU Medical Device Regulation (MDR 2017/745) with notified-body certification and UDI traceability in Europe, and NMPA registration in China.

The key directions of biomedical engineering & implants are:

1. Orthopedic and dental implants (titanium, bio-ceramics, 3D-printed): cementless joint prostheses, hydroxyapatite bone scaffolds and lattice-optimized 3D-printed implants placed under robotic control for osseointegration.
2. Cardiovascular implants (stents, TAVR valves, pacemakers): drug-eluting coronary stents, transcatheter aortic valve replacement (TAVR) systems and connected defibrillators delivered minimally invasively.
3. Neurointerfaces and brain–computer interfaces (BCI): surgically implanted electrode arrays and wireless implants that decode motor or sensory signals for paralysis, blindness and neuromotor disorders.
4. Tissue-engineered biomaterials: medical-grade hyaluronic acid, collagen matrices and cell-seeded engineered skin for wound healing, dermal reconstruction and drug delivery.

Sectoral value chain

[Biocompatible materials] ──> [Imaging & AI design] ──> [Manufacturing (CNC / SLM)]
                                       │
                              (porous lattice, osseointegration)
                                       │
                                       ▼
[Surgical implantation] <─── [Sterilization & QMS] <─── [Regulatory clearance]

Value chain levels

Cross-cutting technologies of the sector:

• Surgical robotics: haptic-boundary robotic arms (Stryker Mako) that map the patient’s bone in 3D and constrain the cutter to the planned implant envelope, raising placement precision.
• Connected implants: pacemakers and ICDs with Bluetooth telemetry (e.g. Abbott Gallant) that stream device status to a clinician app, turning the implant into a monitoring node.
• 3D-printed porous lattices: patient-specific implants with computationally graded porosity that mimics trabecular bone, manufactured by selective laser melting for complex oncology and revision cases.

02US

The United States leads the premium, innovation-driven end of biomedical engineering — surgical robotics, invasive brain–computer interfaces and high-margin cardiovascular implants — funded by an insurance model that pays hundreds of thousands of dollars per advanced procedure.

Surgical robotics & premium orthopedics, invasive BCI, cardiovascular innovation

• Stryker and the Mako platform: Stryker’s Mako SmartRobotics now covers knee, hip and (in full market release from 2026) shoulder arthroplasty, with the handheld Mako RPS entering limited release in February 2026; Stryker reported $11.2 billion in 2025 orthopedic sales.
• Neuralink and Synchron (BCI): Neuralink’s N1 implant and R1 surgical robot are in the PRIME and GB-PRIME early-feasibility trials, with public trackers reporting 21 enrolled participants across five therapeutic programs in four countries and zero serious adverse device events; Synchron’s Stentrode is implanted via the jugular vein without craniotomy.
• Medtronic and cardiovascular implants: the FDA approved Medtronic’s Evolut FX+ TAVR for an expanded Redo-TAVR indication in August 2025, and Medtronic earned the CE Mark for redo-TAVI procedures, extending valve-in-valve therapy for high-risk patients.

03CN

China is the cost-and-scale pole of the industry: state Volume-Based Procurement has driven imported implant prices down by an order of magnitude and pushed domestic manufacturers to majority share in stents and orthopedic prostheses, while the NMPA runs an accelerated track for innovative devices.

Volume-Based Procurement & import substitution, cardiovascular localization, biomaterials and BCI

• VBP and import substitution: national tenders cut the price of a coronary drug-eluting stent from about 13,000 yuan to roughly 700 yuan, and domestic producers now hold the majority of the Chinese implant market, up sharply from roughly a quarter a decade ago; the NMPA innovative-device track clears qualifying products in months rather than years.
• MicroPort Scientific and Lepu Medical: MicroPort and Lepu are among China’s top cardiovascular-device companies, leading the domestic drug-eluting stent and pacemaker rankings built on the VBP winners’ list.
• Bloomage Biotech and biomaterials: Bloomage Biotech is the global volume leader in medical-grade hyaluronic acid, supplying dermal fillers, ophthalmic and orthopedic injectables, and is pivoting into glycoscience and AI-designed glycans; BrainCo (强脑科技) is commercializing non-invasive and medical BCI headsets with NMPA clearance and has filed for a Hong Kong IPO.

04EU

The European Union operates the world’s strictest device regime under MDR 2017/745 — fully enforced from 2024 — and couples it with the region’s largest engineering and medical-imaging clusters in Germany, the Netherlands, Switzerland and France.

MDR 2017/745 strictest regime, engineering & imaging clusters, tissue & biomaterial innovation

• Siemens Healthineers and the imaging cluster: Siemens Healthineers reported €23.4 billion in FY25 revenue (+5% year on year), led by €12.1 billion in imaging, anchoring a German medtech belt alongside B. Braun and Fresenius.
• Straumann and dental implants: Straumann Group reported CHF 2.5 billion in 2025 revenue with 13.7% organic growth and holds about a 30% share of the global dental implant market.
• MDR enforcement and research institutes: full MDR enforcement requires clinical evidence, notified-body certification (TÜV, BSI, SGS), UDI labelling and EUDAMED registration; Fraunhofer IBMT, Inserm (living stents and resorbable valves), Istituto Ortopedico Rizzoli (3D hydroxyapatite bone scaffolds) and CIBER-BBN (polymer nanomedicine) drive the underlying engineering.

05Leading companies and research institutes

06Tech stack and innovations

The biomedical-implant stack joins an implantable hardware core, an imaging-and-robotics delivery layer and a regulatory-quality substrate into one device ecosystem.

1. Robotic-assisted surgery and 3D-printed personalized implants:
   • Haptic-boundary robotic arms (Stryker Mako) build a 3D model of the patient’s bone from CT and constrain the surgeon’s tools to a planned envelope, with Mako Shoulder reaching full market release in 2026 and the handheld Mako RPS entering limited release in February 2026.
   • Zimmer Biomet’s Persona SoluTion and G7 hip systems and 3D-printed metamaterial femoral prostheses use selective laser melting to grade implant porosity for osseointegration, certified under FDA 510(k) clearance.
2. Minimally invasive cardiovascular implants:
   • Transcatheter aortic valve replacement (Medtronic Evolut FX+) is delivered over a catheter and won FDA approval for Redo-TAVR (valve-in-valve) in August 2025 plus a CE Mark for redo-TAVI.
   • Drug-eluting coronary stents (MicroPort FireT, Lepu) deliver antiproliferative drugs from polymer coatings, and connected ICDs (Abbott Gallant) stream status over Bluetooth to a clinician app.
3. Neurointerfaces and connected implants:
   • Invasive BCI implants (Neuralink N1) use a surgical robot (R1) to thread micro-electrode filaments into the motor cortex and transmit decoded neural signals wirelessly, with five therapeutic programs running across four countries.
   • Connected implant telemetry turns pacemakers and ICDs into continuous monitoring nodes, and EU MDR UDI labelling makes every device traceable through EUDAMED.

07Value chains and production pipelines

Production pipeline of a 3D-printed personalized titanium implant (ISO 13485 / ASTM F2924)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Patient CT/MRI imaging │ ───> │ 2. AI lattice design &    │
│    → 3D bone model        │      │    osseointegration CAD   │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Post-process & HAP     │ <─── │ 3. Selective laser        │
│    surface coating        │      │    melting (SLM) of Ti64  │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Sterilization & sterile│ ───> │ 6. Robot-assisted surgical│
│    barrier packaging      │      │    implantation & follow-up│
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Patient CT/MRI imaging and 3D bone model

A high-resolution CT (and where needed MRI) scan of the patient’s joint or defect is segmented into a 3D bone model that captures the exact anatomy and the planned resection envelope for the implant.

Stage 2: AI lattice design and osseointegration CAD

Generative-design software converts the anatomical model into a patient-specific implant with a graded porous lattice whose stiffness matches trabecular bone and whose pore size is tuned for vascularized bone ingrowth.

Stage 3: Selective laser melting (SLM) of titanium

The CAD file is built layer-by-layer by selective laser melting of Ti-6Al-4V powder on an SLM machine, producing the complex internal lattice that conventional CNC machining cannot reach.

Stage 4: Post-processing and hydroxyapatite surface coating

The printed implant is stress-relieved, its mating surfaces are CNC-machined to tolerance, and a plasma-sprayed hydroxyapatite coating is applied to the bone-facing surfaces to promote osseoconduction.

Stage 5: Sterilization and sterile-barrier packaging

The finished implant is gamma- or ethylene-oxide-sterilized, sealed in a validated sterile-barrier pouch with UDI labelling, and assigned a shelf life under ISO 13485 quality management.

Stage 6: Robot-assisted surgical implantation and follow-up

The surgeon loads the patient plan into a robotic platform (e.g. Mako) that guides the cut to the planned envelope, seats the implant, and post-operative imaging plus connected-implant telemetry support the follow-up.